New Paradigms in the Clinical Practice of Inflammatory Bowel Diseases – Live Event

EVENT Summary

Dates

Wednesday, November 30, 2022, 7:00 PM EDT

Location

Virtual

Target Audience

Gastroenterologists, internal medicine specialists, primary care physicians, nurse practitioners, physician assistants, and nurses caring for patients with inflammatory bowel diseases (IBDs)

Format

Live Webinar

Credits

1.25 / AMA PRA Category 1 Credit(s)^TM
1.25 / ANCC Contact Hours

Cost

Free

Program Description

Click to Go to the Event Registration

Inflammatory bowel diseases (IBD), commonly categorized as Crohn’s disease (CD) and ulcerative colitis (UC), are immune mediated chronic inflammatory disorders of the gastrointestinal tract. The etiopathogenesis is multifactorial, with different environmental, genetic, immune mediated, and gut microbial factors playing an important role. The current therapy goals are to improve clinical symptoms, control inflammation, prevent complications, and improve quality of life. Different therapeutic agents are available with their indications, mechanisms of action, and side effects. The field of IBD therapeutics has seen tremendous improvements, and the efficacy of new drug targets such as IL-12/IL-23, the JAK/STAT pathway, and S1P has been established.

Agenda

• Role of the drug targets such as S1P, the JAK/STAT, the IL-12/IL-23 pathway, and biosimilars in managing IBD – Miguel Regueiro, MD
• Case Presentation 1 – Miguel Regueiro, MD
• Discuss the interdisciplinary management of extra-intestinal manifestations in people living with IBD – Francis Farraye, MD
• Case Presentation 2 – Farraye, MD
• Q&A from the Audience and Panel Discussion – Miguel Regueiro, MD/Francis Farraye, MD

Intended Audience

Gastroenterologists, internal medicine specialists, primary care physicians, nurse practitioners, physician assistants, and nurses caring for patients with inflammatory bowel diseases (IBDs).

Commercial Supporters

Supported by educational grants from Pfizer Inc. and Bristol Myers Squibb.

Learning Objectives

• Incorporate biologics, small molecule inhibitors, and biosimilars in the treatment of inflammatory bowel diseases (IBD)
• Assess the interdisciplinary management strategies of extra-intestinal manifestations in people living with IBD

Accredited Providers

Jointly provided by Amedco, a CME/CE company, and MedNet

      

Joint Accreditation

In support of improving patient care, this activity has been planned and implemented by Amedco LLC and MEDNET. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians (ACCME) Credit

Designation Statement

Amedco LLC designates this live activity for a maximum of 1.25 AMA PRA Category 1 Credit(s)^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses (ANCC) Credit

Designation Statement

Amedco LLC designates this activity for a maximum of 1.25 ANCC contact hours.

Additional Credit Information

Nurse Practitioners
The American Association of Nurse Practitioners (AANP) recognizes the Accreditation Council for Continuing Medical Education (ACCME) and the American Nurses Credentialing Center (ANCC) as approved accreditors and allow reciprocity for AANPCP continuing education credit. Maximum of 1.25 hours.

Physician Assistants
AAPA accepts AMA PRA Category 1 Credit(s)^TM for the PRA from organizations accredited by ACCME. Maximum of 1.25 hours.

Staff Disclosures

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

• Kamatham A. Naidu, PhD (MedNet) has no relevant financial relationships.
• Brian Waggoner (MedNet) has no relevant financial relationships to disclose.
• Sheryl Morgan (Amedco) has no relevant financial relationships to disclose.

Faculty

Miguel Regueiro, MD
Professor, Department of Medicine
Chair, Digestive Disease and Surgery Institute
Chair, Department of Gastroenterology, Hepatology, and Nutrition
The Pier C. and Renee A. Borra Family Endowed Chair in Gastroenterology and Hepatology
Cleveland Clinic Lerner College of Medicine of Case Western Reserve University
Cleveland, OH

Francis Farraye, MD
Professor of Medicine
Director, Inflammatory Bowel Disease Center
Division of Gastroenterology and Hepatology
Mayo Clinic
Jacksonville, Florida

Instructions/Technical Requirements

• A desktop or laptop computer with a stable internet connection and audio capability is required to attend. Joining via mobile or tablet is possible but not recommended.
• Times in the portal adjust to your computer; however, some browsers have a separate time zone adjustment.
• For the best viewing experience, we recommend the following browsers: Chrome, Firefox, and Safari. For attendees viewing on Internet Explorer 11, you may experience lags in streaming. To maximize your attendee hub experience, we recommend you not sign in through your company assigned VPN.
• Ensure that your computer’s sound is enabled for your browser and allow permissions to the On24 Attendee Hub platform if necessary.

Cost

Complimentary

Contact

Brian Waggoner
Program Manager
MedNet
brianw@mmhus.net